Hexaquin (Sodium Valproate)

Hexaquin is indicated for several neurological and psychiatric conditions where rapid drug delivery is essential.

• Treatment of generalized tonic‑clonic seizures in adults and children.
• Management of status epilepticus when oral therapy is not feasible.
• Adjunctive therapy for bipolar disorder as a mood stabilizer.
• Short‑term control of breakthrough seizures during medication transitions.
• Use in peri‑operative settings to prevent seizure recurrence.

• Sodium valproate increases the concentration of gamma‑aminobutyric acid (GABA) in the brain by inhibiting GABA transaminase and enhancing GABA synthesis, leading to heightened inhibitory neurotransmission. It also blocks voltage‑gated sodium channels, reducing neuronal excitability, and may modulate calcium channels, collectively stabilizing neuronal membranes and preventing the spread of seizure activity.

Adverse reactions to Hexaquin can vary in frequency and severity.

Common

• Nausea or vomiting.
• Tremor or mild dizziness.
• Transient headache.
• Mild sedation or drowsiness.
• Elevated liver enzymes.
• Weight gain.

Serious

• Hepatotoxicity, including severe liver injury.
• Pancreatitis, presenting with abdominal pain.
• Thrombocytopenia or other blood dyscrasias.
• Hyperammonemic encephalopathy.
• Severe skin reactions such as Stevens‑Johnson syndrome.
• Acute pancreatitis.

Patients and clinicians should consider several safety aspects before initiating Hexaquin therapy.

• Assess liver function tests prior to treatment and monitor periodically.
• Evaluate baseline platelet count and complete blood count.
• Use with caution in patients with a history of pancreatitis.
• Avoid use during pregnancy unless benefits outweigh risks; it is classified as Category D.
• Monitor serum ammonia levels in patients presenting with altered mental status.
• Adjust dosage in patients with renal impairment.
• Counsel about potential weight gain and advise lifestyle measures.

Hexaquin may interact with other medications, influencing its efficacy or safety.

Avoid

• Concurrent use with other antiepileptic drugs that induce hepatic enzymes (e.g., carbamazepine, phenytoin) as they may lower valproate levels.
• Combination with aspirin or other anticoagulants due to increased bleeding risk.
• Co‑administration with lamotrigine without dose adjustment, which can raise lamotrigine concentrations.

Use with caution

• Concurrent use of other hepatotoxic agents (e.g., isoniazid, methotrexate).
• Drugs that displace valproate from plasma proteins (e.g., phenobarbital).
• Oral contraceptives, which may reduce valproate plasma levels.
• High‑protein meals that can affect absorption when switching between oral and IV forms.